Partnering in Immunology

Our growing portfolio of partnerships in immunology focuses on novel target identification, drug discovery and deep disease understanding. We have an established community of academic and biotechnology innovation partners who, together with our own industry-leading scientists, are advancing our search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities. We are also actively pursuing new early-science collaborations in our areas of partnering interest.

Our experience

Boehringer Ingelheim has been involved in research and development in immunology for many years and we continue to proactively invest to build our pipeline and capabilities in this important area.

Scientists in our research and development center for immunology are working together with our academic and industry partners to discover new therapeutic options to treat these chronic, progressive disorders.

Our Immunology research and partnering focus

Our immunology research and development program is anchored firmly by a panel of external collaborations to deliver promising new compounds with the potential to transform the treatment of immune-mediated diseases.

We are seeking collaboration and in-licensing opportunities from early research stage through late pre-clinical development in the following areas:

Crohn’s disease: including specific approaches for fistulizing and refractory ileal Crohn’s disease
Ulcerative colitis
Inflammatory skin diseases: including systemic sclerosis-scleroderma.

Within these areas, our specific research interests offer further opportunities for collaboration:

Human genetics: identification of new therapeutic concepts and biomarkers
Gut & skin epithelial barrier dysfunction: regulation of injury, inflammation and repair, including host-microbiome interactions
Control of aberrant tissue remodeling and fibrosis
Innate immune signaling pathways
Immune regulatory receptors.